Clinical Trials Logo

Clinical Trial Summary

This study is going to test a cold atmospheric plasma device (CAP), in particular a floating electrode-dielectric barrier device (FE-DBD), to treat warts and molluscum. The treatment device in this study generates cold atmospheric plasma (gaseous ionized molecules) to rid the virus from the body. Based on the successes of previous dermatologic studies, FE-DBD is being tested for this study to treat warts and molluscum. Patients will be enrolled to test the efficacy and safety of this device. The duration of the study is 4-12 weeks depending on treatment clearance. The number of lesions will be chosen by the dermatologist. Patients will receive standard of care therapy and/or NTAP depending on the number of lesions.

Clinical Trial Description


Study Design

Related Conditions & MeSH terms

NCT number NCT05070754
Study type Interventional
Source Medical University of South Carolina
Contact Chelsea Shope, BA
Phone 843-754-9577
Email [email protected]
Status Not yet recruiting
Phase Phase 4
Start date October 1, 2021
Completion date December 2021

See also
  Status Clinical Trial Phase
Completed NCT00328991 - Clinical Trial Evaluating Efficacy of Duct Tape for Treatment of Warts N/A
Completed NCT03487549 - Cantharidin and Occlusion in Verruca Epithelium Phase 2
Completed NCT01084824 - A Trial Examining the Treatment of Common Warts With Combination Liquid Nitrogen (LN2) and Cantharidin N/A
Terminated NCT01609530 - Pulsed 1064nm Nd:YAG in the Treatment of Verruca Vulgaris Versus Conventional Therapy With Liquid Nitrogen Cryotherapy N/A
Recruiting NCT04620785 - Photodynamic Therapy in Treatment of Verrucae N/A
Completed NCT04793529 - Is Involucrin Has a Role in Verruca Vulgaris? A Clinical and Immunohistochemical Study N/A
Completed NCT02748902 - Exploratory Study of Efficacy and Safety of Ingenol Mebutate 0.05% Gel for Common Warts on the Hands. Phase 1
Completed NCT02483455 - ALC-919 For The Treatment Of Common Warts Phase 2